Purpose. Current literature on clinical controversies surrounding the use of thrombolytic agents in patients with intermediate-risk pulmonary embolism (PE) is reviewed.
A cute pulmonary embolism (PE) is a major cause of morbidity and mortality, with an incidence of 60-70 cases per 100,000 population and associated 30-day all-cause mortality rates between 9% and 11%. [1] [2] [3] Recurrent PE events are common, with a cumulative prevalence of up to 30% at 10 years after PE diagnosis. Over the long term, chronic thromboembolic pulmonary hypertension (CTEPH) may occur, with an annual incidence of up to 9% at 2 years after PE diagnosis. 3 Guidelines recommend immediate initiation of anticoagulation with either unfractionated heparin (UFH) or low-molecularweight heparin (LMWH) in suspected PE. 3, 4 Thrombolytic therapy rapidly restores pulmonary perfusion; however, the benefits do not outweigh the risks in all patients. 3, 4 Guideline recommendations for use are dependent on proper risk stratification.
The 2-fold objective of this review is to identify clinical controversies surrounding thrombolysis in intermediate-risk PE and to review recent literature on these subjects. We performed a PubMed search of Englishlanguage literature published from 2000 to 2017 using the following MeSH terms: pulmonary embolism, thrombolytic therapy, fibrinolytic therapy, and tissue plasminogen activator. Clinical trials, peer-reviewed guidelines, metaanalyses, and review articles were evaluated for inclusion. Case studies and literature not relevant to current controversies or intermediate-risk patients were excluded. Use of thrombolysis for patients with exclusively high-risk PE or receiving advanced cardiac life support was outside the scope of this review; we refer readers to other sources for information on these topics. [3] [4] [5] [6] Pathophysiology, presentation, and diagnosis PE can lead to pulmonary hypertension by obstructing pulmonary arterial flow and causing hypoxia-related vasoconstriction of the pulmonary arteries mediated by thromboxane A2 and serotonin. 1, 3 This process decreases arterial compliance and increases pulmonary vascular resistance, causing increased right ventricle (RV) afterload, RV dilation, and prolonged RV contraction. Above a pulmonary artery pressure (PAP) of 40 mm Hg, RV contraction is so prolonged that the RV bows into the left ventricle (LV), causing desynchronization and, ultimately, hemodynamic instability. 1 Hypoxemia occurs as a result of decreased cardiac output, ventilation-perfusion mismatch, and compensatory overflow of nonobstructed vessels. PE can be asymptomatic or have clinical manifestations ranging from shortness of breath to circulatory collapse. The most common symptom, dyspnea, is usually acute, but delayed presentations can be seen. 7 Dyspnea may be followed by chest pain, cough, or hemoptysis. 2 Concurrent leg pain may be indicative of concomitant deep vein thrombosis. 2 Less common presentations of PE can include arrhythmias, syncope, significant hypoxemia, and hemodynamic collapse. A diagnosis of PE is suspected on the basis of risk factors and clinical examination
KEY POINTS
• Pharmacists should consider risk stratification, bleeding risk, and contraindications to determine which patients with pulmonary embolism (PE) are the best candidates for thrombolysis.
• Closely monitoring patients with intermediate-risk PE for hemodynamic decompensation, rather than empirically giving thrombolytic therapy, may minimize overall risk; however, no strategy will be effective in every patient.
• Catheter-directed thrombolysis is an emerging option for targeted treatment, so pharmacists should become familiar with dosing recommendations and local practices to optimize this strategy.
findings and confirmed by imaging, as discussed in detail elsewhere.
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Risk stratification
Several factors are useful in identifying patients at risk for poor PE outcomes (Table 1) , among whom mortality rates range from 1% to 65% depending on underlying physiologic response. 1, 3 Mortality risk is affected by thrombus extent and by physiologic reserve. Higher mortality occurs in patients with high-risk, or massive, PE, the defining feature of which is hypotension ( Figure 1 ). Patients who do not meet criteria for high-risk PE but are still in danger of cardiac decompensation fall into the intermediate-risk, or "submassive", PE category. Although hemodynamically stable, these patients have evidence of myocardial strain, which equates to a short-term mortality rate of 5-25%. 1, 3, 4 In the American College of Chest Physicians (CHEST) guidelines, patients with either RV dilation or elevated levels of certain biomarkers are considered to be in the intermediaterisk category. 4 European Society of Cardiology (ESC) guidelines further differentiate patients with PE as being at intermediate-high risk (both RV dilation and elevated biomarkers are present) or intermediate-low risk (only 1 of those 2 findings is present). 3 For normotensive patients, ESC guidelines recommend use of a scoring tool to assess patient risk and guide further risk stratification. 3 The original pulmonary embolism severity index (PESI) was created from registry data using a derivation sample of 10,354 patients with PE. 8 The simplified PESI, used for easier assessment, was derived by removing variables that were not significant independent risk predictors on univariate logistic regression analysis. 9 Patients with a score of class III, IV, or V on the original PESI or a score of at least 1 on the simplified PESI fall into the intermediate-or high-risk PE category. 3 These patients would benefit from further laboratory testing and imaging to identify signs of RV dysfunction and guide care.
Guidelines recommend risk stratification and assessment of the risk of bleeding to determine which patients are the best candidates for thrombolysis. 3, 4 Thrombolytic agents are recommended in patients with high-risk PE (in the CHEST guidelines, this is a grade 2B recommendation; in the ESC guidelines, a IB recommendation). 3, 4 In contrast, thrombolytic therapy is not recommended in most patients with PE not associated with hypotension (in the CHEST guidelines, this is a 1B recommendation; in the ESC guidelines, a IIIB recommendation). 3, 4 However, thrombolytic agents may be considered in select patients who are hemodynamically stable, deteriorate after initiation of anticoagulation, and have a low risk of bleeding. 4 
Thrombolytic therapy
Pharmacology. While anticoagulants are the mainstay of therapy to prevent thrombus accumulation in PE, endogenous fibrinolysis may be 6 Thrombolytic agents are classified by their degree of selectivity for thrombus-bound plasminogen. Streptokinase and urokinase are nonselective agents, activating both circulating and clot-bound plasminogen. These agents have fallen out of favor due to adverse effects and are no longer available in the United States. Fibrinselective agents bind more tightly to fibrin, allowing them to work specifically within the thrombus. 6 Agents in this group include alteplase, tenecteplase, and reteplase; they vary in dosing and half-life (Table 2 ).
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Safety. Bleeding is a major concern with thrombolytic therapy. Events vary from minor bleeds to life-threatening hemorrhage, with intracranial hemorrhage (ICH) being one of the greatest concerns. Investigators who conducted a meta-analysis of data from clinical trials involving use of thrombolytic agents reported an overall rate of major bleeding of 6.6%, with ICH occurring in 1.7% of patients overall.
14 However, reporting of bleeding in clinical trials is influenced by strict inclusion criteria. Registry data, which may provide 15, 16 Due to the high risk of bleeding associated with thrombolysis, many contraindications exist (Table 3) . 4 One retrospective single-center study examined risk factors for bleeding in 62 patients receiving alteplase for PE. 17 The rate of major bleeding was 45%, and 2% of patients experienced ICH. Risk factors evaluated included active bleeding, major surgery in the past 3 weeks, needle puncture at noncompressible sites, age of >75 years, hypertension, gastrointestinal bleeding in the past 3 months, cardiopulmonary resuscitation (CPR) exceeding 10 minutes, intraaortic balloon pump placement, left heart thrombus, stool positive for occult blood, a platelet concentration of <100,000 cells/mm 3 , a bilirubin concentration of >3 mg/dL, and an International Normalized Ratio of >1.7. The presence of at least 1 risk factor (odds ratio [OR], 5.74; 95% confidence interval [CI], 1.78-18.55) and the presence of low body weight (OR, 1.18 for each 10-kg increment below 100 kg; 95% CI, 1.01-1.37) were independently associated with major bleeding on multivariate analysis. Patients with at least 1 risk factor also had a higher mortality rate than those with no risk factors (p = 0.001).
Predicting bleeding risk in patients receiving thrombolytic therapy remains difficult. Age of >65 years and a history of cerebrovascular accident have been strongly and repeatedly associated with ICH. 17, 18 Patients with both of these risk factors are likely to be poor candidates for thrombolytic therapy.
Clinical controversies in intermediate-risk PE
What is the role of systemic thrombolysis in PE? Full-dose thrombolysis. In patients with intermediaterisk PE, the benefit-to-risk ratio of thrombolysis is less apparent than it is in patients with high-or low-risk PE. The PEITHO trial, findings of which were published in 2014, was the largest study to date that included only patients with intermediate-risk PE. 19 This multicenter, prospective, randomized controlled trial enrolled 1,006 patients with RV dysfunction confirmed by echocardiography or computed tomography and elevated troponin levels. They were randomly assigned to either weight-based tenecteplase therapy (30-50 mg) once or placebo, with all patients receiving UFH. The primary outcome was a composite of death from any cause and hemodynamic decompensation or collapse within 7 days. The composite outcome occurred at a significantly lower rate in the tenecteplase group versus the UFH group (2.6% versus 5.6%, p = 0.02), with a number needed to treat (NNT) of 28 patients. In examining individual components of the primary outcome, the investigators found that the association between tenecteplase use and a decreased rate of hemodynamic decompensation remained significant (the rate was 1.6% with tenecteplase use versus 5.0% with placebo use, p = 0.02) but the benefit of thrombolysis in terms of death from any cause did not (all-cause mortality was 1.2% with tenecteplase use versus 1.8% with placebo use, p = 0.42). Hemodynamic collapse was driven by persistent hypotension (3.6% of patients) or a requirement of vasopressors (2.8% of patients), which the investigators noted was of questionable clinical significance. CPR was required in only 1% of patients. Open-label rescue reperfusion was required in 27 patients, 85% of whom were in the placebo group. Several subgroup analyses were performed to evaluate the primary outcome in relation to factors such as weight, immobilization, cancer, history of venous thromboembolism, time of symptom onset, heart rate, and respiratory rate. The only factor found to have a significant effect was respiratory rate, with a rate of ≥24 respirations per minute being associated with a significant difference in the primary outcome favoring tenecteplase versus placebo use (OR, 0.062; 95% CI, 0.008-0.489; p = 0.028).
The safety analysis portion of the PEITHO trial showed that tenecteplase use, as compared with placebo use, was associated with increased rates of major bleeding (6.3% versus 1.2%, p < 0.001) and stroke within 7 days (2.4% versus 0.2%, p = 0.003); the corresponding values for number needed to harm were 19 and 45 patients, respectively. Twelve strokes occurred in the tenecteplase group; 10 were hemorrhagic. Of the 10 patients with ICH, 6 were female and all were at least 65 years of age. At 30 days, 40% of patients who developed ICH had died, 40% had no or slight disability, and 10% had moderate disability; the remaining 10% of surviving patients were not evaluated for disability. Disability was determined using the modified Rankin scale, which assesses neurologic disability after a stroke. 20 The observed high rate of ICH was consistent with registry data and should give clinicians pause. 15 It may be prudent for clinicians to closely monitor patients with intermediate-risk PE for signs of hemodynamic decompensation rather than empirically giving thrombolytic therapy to all patients. With close monitoring, patients who decompensate can quickly be given rescue reperfusion. This strategy may minimize overall risk; however, no strategy will be effective in every patient. 21 Results of a meta-analysis of data on 2,115 patients treated with thrombolytic agents, 71% of whom had intermediate-risk PE, stand in contrast to the PEITHO trial findings. 22 This analysis included data from the PEITHO trials and trials of low-dose thrombolysis and catheter-directed thrombolysis (CDT). It showed a decrease in all-cause mortality with thrombolytic therapy versus placebo use (2.2% versus 3.89%, p = 0.01; NNT, 59); the difference remained significant (1.4% versus 2.9%, p = 0.03) when only hemodynamically stable patients with RV dysfunction were included in the analysis. The rate of major bleeding was elevated with thrombolytic versus placebo use (9.2% versus 3.4%, p < 0.001), as was the rate of ICH (1.5% versus 0.2%, p = 0.02). However, no significant between-group difference was found in rates of major bleeding in patients 65 years of age or younger (2.8% with thrombolytic use and 2.3% with placebo use, p = 0.89). An analysis of net clinical benefit comparing mortality benefits and ICH risk with use of thrombolytic therapy (in this analysis, an ICH event was weighted as 0.75 times a PE mortality event) showed a net benefit of 0.8% (95% CI, 0.65-1.01%).
Data on the long-term effects of thrombolytic reperfusion on chronic conditions, such as CTEPH and rightsided heart failure, are limited. Recently, the PEITHO investigators published data from an extended follow-up of 709 patients assigned to tenecteplase or placebo use for intermediate-risk PE. 23 The median follow-up time was 38 months (interquartile range, 25-55 months). The difference in rates of death from any cause remained nonsignificant at 2 years (20.3% with tenecteplase use and 18.0% with placebo use, p = 0.43). A subset of 376 patients underwent evaluation for CTEPH; there was no significant difference in CTEPH diagnosis rates (2.1% with tenecteplase therapy and 3.2% with placebo use, p = 0.79). There was also no significant between-group difference in terms of the proportion of patients reporting persistent clinical symptoms or meeting criteria for New York Heart Association class III or IV heart failure. As the longest study of patients with intermediate-risk PE receiving thrombolytic therapy to date, the PEITHO study showed no decrease in mortality or long-term complications associated with thrombolytic use. These findings strengthen the argument to closely monitor intermediate-risk patients and administer thrombolytic agents only to those exhibiting signs of cardiovascular deterioration, as long-term sequelae are unlikely to be affected.
Low-dose thrombolysis. Due to the high risk of bleeding with systemic thrombolysis, alternative strategies have been investigated. In terms of treatment, PE is unique among arterial thrombotic conditions, as pulmonary arteries receive the entirety of cardiac output. Therefore, it may be possible to achieve therapeutic concentrations of thrombolytic agents within the pulmonary arteries using a lower dose than is required for other indications, such as myocardial infarction (MI) and ischemic stroke. 24 Low-dose thrombolysis, defined as a dose of ≤50% of the normal systemic dose, has been examined to investigate this theory.
The MOPETT trial, results of which were published in 2013, included 121 patients with PE who were ineligible for full-dose thrombolysis. 24 Patients were randomly assigned to receive alteplase 50 mg over 1 hour plus heparin or heparin alone. The primary outcome was development of CTEPH at 28 months.
Patients receiving alteplase had a significantly lower rate of CTEPH development than controls (16% versus 57%, p < 0.001). Analysis of secondary endpoints showed no significant difference in terms of recurrent PE (there were no cases with alteplase use, while 5% of controls had a recurrence; p = 0.08) or the total mortality rate (1.6% in alteplase recipients and 5.0% in controls, p = 0.30). No bleeding events were reported in either group. The researchers concluded that low-dose alteplase was safe and effective in the treatment of intermediate-risk PE.
While this trial showed that lowdose thrombolysis was associated with a reduction in the occurrence of the primary endpoint of CTEPH, the results should be interpreted with caution. The MOPETT trial was a singlecenter, open-label trial involving very few patients. It was not powered to detect a difference in mortality; it was powered to detect only a difference in development of CTEPH. Patients were excluded if they were eligible for fulldose thrombolysis. While 68% of patients had elevated troponin or B-type natriuretic peptide levels, only 21% had RV enlargement. 24 Therefore, the study results may not be applicable to all candidates for thrombolytic treatment. Additional criticism pertains to the unusually high rate of CTEPH reported in the MOPETT study. At 28 months, 57% of patients in the control group had diagnosed CTEPH. 24 However, previous reports indicated CTEPH rates of 5-9% at 24 months after PE diagnosis. 3, 25 In the MOPETT trial, diagnosis of CTEPH was done via echocardiography, which only estimates systolic PAP. Right heart catheterization, which identifies mean PAP, should be used for diagnosis. 26 The high rate of pulmonary hypertension diagnosis in the MOPETT study population is concerning and possibly affected the trial outcome. While the lack of bleeding events indicated that lowdose thrombolysis is likely safe, this aspect of the trial has also been criticized, as bleeding was not defined.
A limited number of other studies have examined low-dose thrombolysis in the treatment of PE. A meta-analysis of 5 trials involving a total of 440 patients included 2 trials comparing low-dose alteplase with heparin and 3 trials comparing low-and full-dose alteplase. 27 The studies comparing lowdose thrombolytic therapy with heparin use showed no significant difference in all-cause mortality (OR, 0.63; 95% CI, 0.12-3.34), recurrent PE (OR, 0.13; 95% CI, 0.01-2.64), or major bleeding (OR, 0.73; 95% CI, 0.14-3.98). The studies comparing low-and full-dose thrombolytic therapy similarly showed no difference in all-cause mortality (OR, 0.88; 95% CI, 0.23-3.37) or recurrent PE (OR, 0.96; 95% CI, 0.30-3.04); however, in those studies the risk of major bleeding was decreased with low-dose thrombolytic therapy (OR, 0.33; 95% CI, 0.12-0.91). This meta-analysis indicated that low-dose thrombolysis decreases the risk of bleeding, but the implications for efficacy remain unclear. Recently, an analysis of registry data on 3,768 patients showed that patients receiving low-dose thrombolysis had an increased need for treatment escalation, defined as vasopressor initiation, rescue reperfusion, ventilation initiation, embolectomy, CDT, inferior vena cava filter placement, or CPR (escalation rates were 53.8% with low-dose therapy and 41.4% with fulldose therapy, p < 0.01). 28 There was no significant between-group difference in bleeding rates. The study results reported to date suggest that low-dose thrombolysis may have decreased efficacy relative to full-dose thrombolysis; however, full publication is pending.
Clinical application. Balancing the risk of bleeding with the benefits of thrombolytic therapy can be challenging. Thrombolytic therapy decreases hemodynamic decompensation, but likely not mortality, in patients with intermediate-risk PE. In addition, it is associated with high rates of bleeding and ICH, which are difficult to predict. For these reasons, use of thrombolysis in intermediate-risk PE should be limited to the population that exhibits sustained hypotension despite appropriate anticoagulation, assuming that Systemic thrombolysis e no major bleeding risk factors or contraindications exist (Figure 2 ).
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The CHEST guidelines recommend systemic thrombolytic therapy in patients who develop hypotension or other signs of deterioration, including tachycardia, worsening gas exchange, progressive RV dysfunction on echocardiography, increased levels of cardiac biomarkers, and signs of shock (this is a grade 2C recommendation). 4 ESC guidelines recommend rescue reperfusion in patients with RV dysfunction and elevated cardiac biomarkers as soon as signs of hemodynamic decompensation appear (a class IB recommendation). 3 In contrast, guidelines make no recommendation regarding the use of low-dose thrombolysis due to the limited clinical data available regarding that form of therapy. 3, 4 Additional studies involving larger patient populations are needed, but current literature does not support use of low-dose thrombolysis in clinical practice.
When indicated, thrombolytic therapy should be selected on the basis of clinical evidence and differences in pharmacologic properties and pricing (Table 2) . [10] [11] [12] [13] Alteplase and tenecteplase are the most widely used agents; however, only alteplase carries a Food and Drug Administration (FDA) indication for PE. 10, 12 Alteplase has been used in more clinical studies, but tenecteplase was used in the largest study to date and, unlike alteplase, is dose-adjusted for weight. 19, 29 A meta-analysis of data from studies involving 2,057 patients with PE indicated that use of tenecteplase versus alteplase was associated with higher risks of fatal bleeding (OR, 7.32; 95% CI, 1.64-32.63) and ICH (OR, 1.09; 95% CI, 0.27-4.40). 30 However, the evaluated studies of tenecteplase included older patients (advanced age is a risk factor for bleeding), which could have confounded the results. Our literature search identified no published report of a head-to-head comparison of thrombolytic agents for treatment of PE. The decision of which agent to use should ultimately be based on local needs and formulary requirements.
In addition to the choice of thrombolytic agent, anticoagulation must be considered. Anticoagulation with UFH or LMWH is preferred in the acute period. 3, 4 Advantages of UFH versus LMWH include a shorter half-life and quick reversibility if bleeding occurs. In a study of 20,479 patients receiving both anticoagulation and thrombolysis for MI, patients randomly assigned to receive LMWH versus UFH had higher rates of major bleeding at 48 hours (1.4% versus 1.0%, p = 0.004) and at 30 days (2.1% versus 1.4%, p < 0.001). 31 No statistical difference in ICH was found. In the MAPPET-3 trial, results of which were published in 2002, UFH was used as an adjunct to thrombolytic therapy in all patients, and no significant differences in major bleeding or ICH were found. 32 In the PEITHO trial (results were published in 2014), 34% of patients initially received LMWH but were switched to UFH upon treatment randomization. 19 As mentioned previously, the PEITHO study showed significant increases in major bleeding and ICH with thrombolytic use. Guidelines recommend LMWH over UFH for initial anticoagulation except when patients receive thrombolysis, in which case UFH is preferred. 3, 4 Unfortunately, LMWH may be initiated before the need for thrombolytic therapy can be determined; in that event, patients may be transitioned to UFH.
To decrease bleeding, the alteplase labeling recommends that anticoagulant therapy should be withheld until the end of thrombolytic infusion or pending normalization of activated partial thromboplastin time to less than 2 times normal. 10 Guidelines are ambivalent, allowing for either continuation or suspension of anticoagulation. 3, 4 In contrast, clinical trial protocols have routinely allowed continuation of parenteral anticoagulation during thrombolytic therapy. To our knowledge, no head-to-head comparison of these strategies exists. The decision to hold or continue anticoagulation during thrombolytic therapy should be individualized according to the risks of bleeding and hemodynamic decompensation.
Is CDT safe and effective for PE? Recently, CDT has become an increasingly popular option for PE treatment. 33 This strategy involves local administration of thrombolytic therapy, in addition to use of mechanical thrombolytic methods, thereby achieving therapeutic improvement with a lower risk of bleeding. Multiple mechanical techniques exist and can be combined with thrombolytic agents in a treatment approach referred to as pharmacologic CDT. 34, 35 Addition of a thrombolytic agent to mechanical CDT has been shown to increase efficacy rates from 87% to 91%. 36 Pharmacologic CDT may also be performed as ultrasound-assisted thrombolysis (USAT). USAT involves the use of high-frequency, low-power ultrasound waves to augment thrombolytic action by increasing thrombus permeability and drug penetration. 34 Clinical evidence. Pharmacologic CDT has been studied in multiple trials (Table 4) ; however, most were retrospective studies with less than 100 patients. [37] [38] [39] [40] The prospective ULTIMA trial (results were published in 2014) involved 59 patients with intermediaterisk PE. 38 In addition to UFH, patients were randomly assigned to receive USAT with alteplase or no pharmacologic thrombolysis. The primary outcome was the change in the RV/LV ratio at 24 hours. Relative to mean baseline RV/LV values, the USAT group had a significant decrease at 24 hours (from 1.28 to 0.99, p < 0.001), while the control group did not (the mean RV/LV ratio declined from 1.20 to 1.17, p = 0.31). The USAT group also had a significant (p = 0.001) decrease in the mean RV/LV ratio relative to the control group. At 90 days, both groups had a significant decrease in the RV/LV ratio, with no significant difference between groups. No major bleeding events were reported. The SEATTLE II study, which involved 150 patients with intermediate-or high-risk PE, yielded similar results. 39 All patients in this prospective trial received USAT with alteplase. The prima- 40 Patients received alteplase at varying doses and durations. All groups were found to have similar reductions in the mean RV/LV ratio at 48 hours (p < 0.001), with only 3 major bleeding incidents and 1 instance of ICH. These results indicated that compared with full-dose CDT, lower-dose CDT administered over shorter time frames provides equivalent efficacy; however, a definitive interpretation of these findings must await full publication of the study results.
Relative to systemic thrombolytic therapy, local delivery of thrombolytic agents via CDT is associated with decreased markers of myocardial strain and lower rates of bleeding. [38] [39] [40] However, data on clinical endpoints (e.g., mortality) and long-term safety data are lacking, and no prospective comparisons with systemic thrombolysis exist. Despite its seemingly safe profile, some patients may not be good candidates for CDT, and contraindications must be considered. Catheter-related complications include artery perforation with pulmonary hemorrhage, catheter-site hematoma, bradyarrhythmia or heart block, pericardial tamponade, contrast medium-related acute kidney injury, and showering of distal emboli. 3, 35, 36, 41 A meta-analysis of data on 594 patients receiving CDT indicated a 7.9% rate of minor procedural complications and a 2.4% rate of major complications. 41 Guidelines recommend CDT only for patients who cannot undergo systemic thrombolysis due to a high risk of bleeding or who have failed systemic thrombolysis (this is a CHEST grade 2C recommendation and an ESC class IIbB recommendation). 3, 4 Future studies detailing more clinically relevant and longer-term outcomes will help determine the role of CDT in clinical practice.
Clinical application. If CDT ultimately proves to be appropriate for wide use, this method of intervention may pose challenges in terms of practicality. Appropriate equipment and clinician expertise, which may not be available at every institution, are needed to safely perform CDT. 36 Knowledge of local resources and practices will prove helpful in selecting the best treatment strategy.
Dosing of thrombolytic agents during CDT can be challenging, as CDT is not an FDA-approved indication for the thrombolytic agents. The dose should be lower than that required for systemic thrombolysis, defined by some clinicians as no more than 30 mg of a thrombolytic agent. 35, 36 Treatment of patients with bilateral PE requires 2 catheters, which may affect the dosing strategy. Dosing was variable in clinical trials (Table 4) . [38] [39] [40] Some institutions have local protocols, and resources may be available on the websites of CDT device makers. The EKOS device (BTG Interventional Medicine, West Conshohocken, PA) website provides a drug reconstitution chart with dilution instructions (Table 5) . 42 This product's instructions call for a minimum infusion rate of 5 mL/hr to maintain catheter patency, with a maximum infusion rate of 35 mL/hr. 43 Alteplase is recommended for use within 8 hours of reconstitution; however, studies have shown alteplase to be stable for up to 24 hours. 10, 44 Dilution of alteplase yields a lower concentration than the commercially available 1-mg/mL solution. Stability and bioactivity testing of alteplase indicated that it is stable when diluted to 0.01 mg/mL in 0.9% sodium chloride injection. 45 
Conclusion
The use of thrombolysis in the treatment of intermediate-risk PE is complicated by high rates of bleeding and should be limited to patients who clinically deteriorate rather than given as a standard-of-care treatment in this population. Data for low-dose thrombolysis remain limited.
